The VRI’s scientific strategic plan is organized in 6 integrated research programs and structured around common scientific, logistic and administrative cores to conduct researches aimed at developing an effective vaccine against HIV/AIDS, HCV and emerging infectious diseases. The objectives of the VRI are highly specific, measurable and achievable.
The overarching goal is the generation of novel Dendritic Cell (DC) based vaccine candidates in the field of preventive and therapeutic vaccines inducing potent neutralizing and non-neutralizing antibody responses and T cell responses (for therapeutic vaccines).
- the integration of a transdisciplinary approach from basic science in the field of immunology, virology, translational researches to the development of an innovative therapeutic and prophylactic clinical program. This program is based on an innovative clinical platform including clinical sites in France and in Dallas (Baylor Institute for Immunology Research), an immunomonitoring platform (Mondor Immunomonitoring Center) for the evaluation of vaccine elicited immune responses, and a Biostatistics and Bioinformatics core (U1219 ISPED Bordeaux). The clinical program includes a social and human science project for the evaluation of the social impact (dissemination, recruitment of volunteers, social media network) of HIV vaccines.
- the development of a discovery and innovative platform for better characterizing in vivo responses to our portfolio of candidate vaccines: Humanized mice models, integrated analysis of multiparametric mass spectrometry or CyTOF, in vivo imaging, or next-generation sequencing. Thanks to the transversal Biostatistics and Bioinformatics core, a systematic integrated analysis of data generated in preclinical and clinical studies are performed in order to identify correlates of protection or control of viral replication and to model vaccine strategies. Our long-term goal, besides the development of vaccine that will be tested in phase IIb clinical trials, is to model the mechanisms of vaccine response for saving resources, volunteers and for accelerating the clinical development of candidate vaccines. These tools will be instrumental for evaluation of other vaccines or investigational therapies.
- we have completed the preclinical evaluation and the selection of the best-in-class ex vivo DC vaccine that have been developed in a phase II therapeutic trial in 2015 (DALIA and ANRS VRI04 DALIA 2 trial to come) and Dendritic Cell-targeting fusion proteins, including the selection of HIV antigens, that will be manufactured in 2016-2017 for therapeutic and prophylactic HIV phase I/II clinical trials (VRI06 and VRI07 trials). Selection of a CMO vendor for bioproduction of these vaccines according to the good manufacturing practices (cGMP) was realized, enabling NHP toxicity testing before the initiation of a phase I clinical trial in 2018.